Secukinumab, a first-in-class IL-17 inhibitor, has consistently demonstrated its efficacy in axSpA across several phase III RCTs as part of a comprehensive development program, including the MEASURE trials (13–25) in ankylosing spondylitis (AS) and the PREVENT trial (26) in nr-axSpA. Here, IL17A is linked to ankylosing spondylitis.